Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Growth Metrics

Marimed (MRMD) Current Deferred Revenue (2016 - 2025)

Marimed has reported Current Deferred Revenue over the past 11 years, most recently at $1.4 million for Q4 2025.

Quarterly Current Deferred Revenue rose 4.89% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 4.89% year-over-year, with the annual reading at $1.4 million for FY2025, 4.89% up from the prior year.
Current Deferred Revenue was $1.4 million for Q4 2025 at Marimed, down from $1.7 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $1.7 million in Q3 2025 and troughed at $1.3 million in Q4 2024.